HK Stock MarketDetailed Quotes

02196 FOSUN PHARMA

Watchlist
  • 14.320
  • +0.160+1.13%
Market Closed Nov 29 16:08 CST
38.16BMarket Cap16.18P/E (TTM)

FOSUN PHARMA Key Stats

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Turnover
0.69%30.91B
-4.38%20.38B
-6.56%10.16B
-5.85%41.25B
-2.92%30.7B
0.16%21.32B
4.71%10.87B
12.73%43.81B
16.91%31.62B
26.10%21.28B
Operating income
0.69%30.91B
-4.38%20.38B
-6.56%10.16B
-5.85%41.25B
-2.92%30.7B
0.16%21.32B
4.71%10.87B
12.73%43.81B
16.91%31.62B
26.10%21.28B
Cost of sales
----
2.20%-10.46B
----
6.80%-21.6B
----
7.60%-10.7B
----
-14.53%-23.17B
----
-40.23%-11.58B
Operating expenses
-0.70%-15.89B
2.20%-10.46B
4.10%-5.08B
6.80%-21.6B
6.70%-15.78B
7.60%-10.7B
9.66%-5.29B
-14.53%-23.17B
-24.03%-16.91B
-40.23%-11.58B
Gross profit
0.68%15.02B
-6.57%9.92B
-8.90%5.08B
-4.79%19.65B
1.43%14.92B
9.41%10.62B
23.34%5.58B
10.77%20.64B
9.68%14.71B
12.56%9.7B
Selling expenses
8.78%-6.59B
15.87%-4.27B
10.93%-2.24B
-5.90%-9.71B
-11.23%-7.23B
-21.46%-5.07B
-21.70%-2.52B
-0.77%-9.17B
0.94%-6.5B
0.86%-4.18B
Administrative expenses
0.77%-3.14B
-2.17%-2.15B
-1.13%-1B
-14.80%-4.5B
-20.61%-3.17B
-22.11%-2.1B
-26.17%-991.09M
-18.15%-3.92B
-16.73%-2.63B
-14.44%-1.72B
Research and development expenses
16.07%-2.65B
12.77%-1.86B
14.38%-829.57M
-1.02%-4.35B
-10.22%-3.16B
-16.81%-2.13B
-20.31%-968.87M
-12.11%-4.3B
-18.60%-2.86B
-16.98%-1.83B
Profit from asset sales
-60.10%2.51M
----
185.51%434.1K
----
-95.50%6.3M
----
-173.65%-507.68K
----
2,026.44%140.1M
----
Revaluation surplus
-113.18%-106.25M
----
86.36%-20.14M
----
141.76%806.34M
----
89.13%-147.61M
----
-245.96%-1.93B
----
-Changes in the fair value of other assets
-113.18%-106.25M
----
86.36%-20.14M
----
141.76%806.34M
----
89.13%-147.61M
----
-245.96%-1.93B
----
Impairment and provision
74.38%-95.41M
34.39%-38.04M
58.87%-10.53M
-101.82%-131.93M
-189.88%-372.49M
-153.61%-57.98M
-328.87%-25.6M
11.68%-65.37M
51.81%-128.49M
-54.42%-22.86M
-Other impairment is provision
74.38%-95.41M
34.39%-38.04M
58.87%-10.53M
-101.82%-131.93M
-189.88%-372.49M
-153.61%-57.98M
-328.87%-25.6M
11.68%-65.37M
51.81%-128.49M
-54.42%-22.86M
Operating interest expense
----
-17.60%-709.55M
----
----
----
-37.47%-603.38M
----
----
----
---438.91M
Special items of operating profit
-29.30%1.76B
-80.38%194.7M
-49.69%416.77M
353.64%1.09B
-24.67%2.49B
2,266.92%992.21M
-46.80%828.41M
-91.36%239.26M
62.78%3.3B
-97.11%41.92M
Operating profit
-3.32%3.96B
-33.52%1.09B
-22.91%1.3B
-40.08%2.05B
4.02%4.1B
5.12%1.64B
68.38%1.69B
-19.44%3.43B
-22.64%3.94B
-43.83%1.56B
Financing income
----
----
----
28.66%363.65M
----
----
----
--282.64M
----
----
Financing cost
-13.03%-854.56M
----
-7.26%-280.22M
-37.46%-1.32B
-99.46%-756.08M
----
-144.62%-261.26M
---963.81M
3.66%-379.07M
----
Share of profits of associates
----
-15.29%947.2M
----
15.36%2.39B
----
24.43%1.12B
----
1.60%2.07B
----
-2.92%898.58M
Share of profit from joint venture company
----
-10.47%-105.88M
----
13.63%-202.03M
----
3.74%-95.84M
----
5.44%-233.93M
----
-6.13%-99.56M
Special items of earning before tax
27.58%-36.02M
----
93.06%-2.94M
----
73.78%-49.74M
----
-410.57%-42.38M
----
-474.73%-189.71M
----
Earning before tax
-6.71%3.07B
-27.44%1.93B
-26.46%1.02B
-28.46%3.28B
-2.33%3.29B
12.85%2.66B
56.00%1.38B
-24.20%4.58B
-27.76%3.37B
-28.62%2.36B
Tax
13.40%-553.05M
37.49%-381.47M
14.16%-232.2M
41.06%-369.5M
-4.43%-638.65M
-19.87%-610.25M
-11.16%-270.51M
41.21%-626.92M
16.37%-611.54M
7.55%-509.09M
After-tax profit from continuing operations
-5.10%2.52B
-24.45%1.55B
-29.44%786.22M
-26.46%2.91B
-3.83%2.65B
10.92%2.05B
72.94%1.11B
-20.55%3.95B
-29.87%2.76B
-32.84%1.85B
Earning after tax
-5.10%2.52B
-24.45%1.55B
-29.44%786.22M
-26.46%2.91B
-3.83%2.65B
10.92%2.05B
72.94%1.11B
-20.55%3.95B
-29.87%2.76B
-32.84%1.85B
Minority profit
36.99%507.88M
21.36%324.93M
38.66%176.49M
134.84%508.8M
14.66%370.74M
-12.93%267.75M
-29.98%127.28M
-12.48%216.66M
-12.66%323.34M
13.38%307.51M
Profit attributable to shareholders
-11.93%2.01B
-31.33%1.22B
-38.22%609.73M
-35.81%2.4B
-6.29%2.28B
15.68%1.78B
113.39%986.97M
-20.97%3.74B
-31.66%2.44B
-37.89%1.54B
Basic earnings per share
-12.79%0.75
-31.34%0.46
-37.84%0.23
-37.06%0.9
-8.51%0.86
11.67%0.67
105.56%0.37
-22.70%1.43
-32.37%0.94
-38.14%0.6
Diluted earnings per share
-11.76%0.75
-31.34%0.46
-37.84%0.23
-37.06%0.9
-9.57%0.85
11.67%0.67
105.56%0.37
-22.70%1.43
-32.37%0.94
-38.14%0.6
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
Auditor
--
--
--
Ernst & Young Huaming Certified Public Accountants (Special General Partnership)
--
--
--
Ernst & Young Huaming Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Turnover 0.69%30.91B-4.38%20.38B-6.56%10.16B-5.85%41.25B-2.92%30.7B0.16%21.32B4.71%10.87B12.73%43.81B16.91%31.62B26.10%21.28B
Operating income 0.69%30.91B-4.38%20.38B-6.56%10.16B-5.85%41.25B-2.92%30.7B0.16%21.32B4.71%10.87B12.73%43.81B16.91%31.62B26.10%21.28B
Cost of sales ----2.20%-10.46B----6.80%-21.6B----7.60%-10.7B-----14.53%-23.17B-----40.23%-11.58B
Operating expenses -0.70%-15.89B2.20%-10.46B4.10%-5.08B6.80%-21.6B6.70%-15.78B7.60%-10.7B9.66%-5.29B-14.53%-23.17B-24.03%-16.91B-40.23%-11.58B
Gross profit 0.68%15.02B-6.57%9.92B-8.90%5.08B-4.79%19.65B1.43%14.92B9.41%10.62B23.34%5.58B10.77%20.64B9.68%14.71B12.56%9.7B
Selling expenses 8.78%-6.59B15.87%-4.27B10.93%-2.24B-5.90%-9.71B-11.23%-7.23B-21.46%-5.07B-21.70%-2.52B-0.77%-9.17B0.94%-6.5B0.86%-4.18B
Administrative expenses 0.77%-3.14B-2.17%-2.15B-1.13%-1B-14.80%-4.5B-20.61%-3.17B-22.11%-2.1B-26.17%-991.09M-18.15%-3.92B-16.73%-2.63B-14.44%-1.72B
Research and development expenses 16.07%-2.65B12.77%-1.86B14.38%-829.57M-1.02%-4.35B-10.22%-3.16B-16.81%-2.13B-20.31%-968.87M-12.11%-4.3B-18.60%-2.86B-16.98%-1.83B
Profit from asset sales -60.10%2.51M----185.51%434.1K-----95.50%6.3M-----173.65%-507.68K----2,026.44%140.1M----
Revaluation surplus -113.18%-106.25M----86.36%-20.14M----141.76%806.34M----89.13%-147.61M-----245.96%-1.93B----
-Changes in the fair value of other assets -113.18%-106.25M----86.36%-20.14M----141.76%806.34M----89.13%-147.61M-----245.96%-1.93B----
Impairment and provision 74.38%-95.41M34.39%-38.04M58.87%-10.53M-101.82%-131.93M-189.88%-372.49M-153.61%-57.98M-328.87%-25.6M11.68%-65.37M51.81%-128.49M-54.42%-22.86M
-Other impairment is provision 74.38%-95.41M34.39%-38.04M58.87%-10.53M-101.82%-131.93M-189.88%-372.49M-153.61%-57.98M-328.87%-25.6M11.68%-65.37M51.81%-128.49M-54.42%-22.86M
Operating interest expense -----17.60%-709.55M-------------37.47%-603.38M---------------438.91M
Special items of operating profit -29.30%1.76B-80.38%194.7M-49.69%416.77M353.64%1.09B-24.67%2.49B2,266.92%992.21M-46.80%828.41M-91.36%239.26M62.78%3.3B-97.11%41.92M
Operating profit -3.32%3.96B-33.52%1.09B-22.91%1.3B-40.08%2.05B4.02%4.1B5.12%1.64B68.38%1.69B-19.44%3.43B-22.64%3.94B-43.83%1.56B
Financing income ------------28.66%363.65M--------------282.64M--------
Financing cost -13.03%-854.56M-----7.26%-280.22M-37.46%-1.32B-99.46%-756.08M-----144.62%-261.26M---963.81M3.66%-379.07M----
Share of profits of associates -----15.29%947.2M----15.36%2.39B----24.43%1.12B----1.60%2.07B-----2.92%898.58M
Share of profit from joint venture company -----10.47%-105.88M----13.63%-202.03M----3.74%-95.84M----5.44%-233.93M-----6.13%-99.56M
Special items of earning before tax 27.58%-36.02M----93.06%-2.94M----73.78%-49.74M-----410.57%-42.38M-----474.73%-189.71M----
Earning before tax -6.71%3.07B-27.44%1.93B-26.46%1.02B-28.46%3.28B-2.33%3.29B12.85%2.66B56.00%1.38B-24.20%4.58B-27.76%3.37B-28.62%2.36B
Tax 13.40%-553.05M37.49%-381.47M14.16%-232.2M41.06%-369.5M-4.43%-638.65M-19.87%-610.25M-11.16%-270.51M41.21%-626.92M16.37%-611.54M7.55%-509.09M
After-tax profit from continuing operations -5.10%2.52B-24.45%1.55B-29.44%786.22M-26.46%2.91B-3.83%2.65B10.92%2.05B72.94%1.11B-20.55%3.95B-29.87%2.76B-32.84%1.85B
Earning after tax -5.10%2.52B-24.45%1.55B-29.44%786.22M-26.46%2.91B-3.83%2.65B10.92%2.05B72.94%1.11B-20.55%3.95B-29.87%2.76B-32.84%1.85B
Minority profit 36.99%507.88M21.36%324.93M38.66%176.49M134.84%508.8M14.66%370.74M-12.93%267.75M-29.98%127.28M-12.48%216.66M-12.66%323.34M13.38%307.51M
Profit attributable to shareholders -11.93%2.01B-31.33%1.22B-38.22%609.73M-35.81%2.4B-6.29%2.28B15.68%1.78B113.39%986.97M-20.97%3.74B-31.66%2.44B-37.89%1.54B
Basic earnings per share -12.79%0.75-31.34%0.46-37.84%0.23-37.06%0.9-8.51%0.8611.67%0.67105.56%0.37-22.70%1.43-32.37%0.94-38.14%0.6
Diluted earnings per share -11.76%0.75-31.34%0.46-37.84%0.23-37.06%0.9-9.57%0.8511.67%0.67105.56%0.37-22.70%1.43-32.37%0.94-38.14%0.6
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKAS
Audit Opinions ------Unqualified Opinion------Unqualified Opinion----
Auditor ------Ernst & Young Huaming Certified Public Accountants (Special General Partnership)------Ernst & Young Huaming Certified Public Accountants (Special General Partnership)----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data